Loading...
NPI 1689349102 · Peachtree Corners, GA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Advanced Medical Diagnostics Of Texas, LLC is a clinical medical laboratory provider located in Peachtree Corners, Georgia. This profile covers 1 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Advanced Medical Diagnostics Of Texas, LLC |
| Address | 333 Research Ct Ste 200 |
| City | Peachtree Corners |
| State | GA |
| ZIP | 30092 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 16, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.9M |
| Medicaid | $1.4K |
Payer mix is heavily weighted to Medicare: the provider reports $2.9M in total Medicare revenue versus $1.4K in total Medicaid revenue, making Medicare the dominant payer by several orders of magnitude and indicating the entity is effectively a Medicare-focused billing operation. Medicaid activity is present but immaterial in scale compared with Medicare.
Medicare revenue is extremely concentrated in a single CPT/HCPCS line: top 3 Medicare codes account for 100.0% of Medicare revenue, and K1034 alone is reported at 246.1K claims, $12 avg paid/claim, $3M revenue (100.0% of this provider's total Medicare revenue). That concentration and the listed ranking (rank #119 of 30143; 100th percentile; extreme outlier) mark the provider as a national outlier for this specific code.
The provider’s code mix and taxonomy (Clinical Medical Laboratory) point to a business model centered on COVID-19 testing logistics rather than a broad diagnostic lab footprint: K1034 describes provision of nonprescription self-administered COVID-19 tests, and the Medicaid mix includes molecular testing codes U0003 and U0005, consistent with a mix of OTC test distribution and some PCR processing. This pattern suggests operations optimized for high-volume COVID test distribution and selective lab-based confirmatory testing.
Medicaid revenue is also concentrated: precomputed top 3 Medicaid codes account for 100.0% of Medicaid revenue, with K1034 responsible for 76.0% ($893 of total Medicaid revenue), U0003 for 24.0% ($282), and U0005 for 0.0% ($0). All three Medicaid codes are described as typical, unremarkable volumes in-state (K1034 rank #3 of 5, 50th percentile; U0003 rank #29 of 39, 24th percentile; U0005 rank #29 of 41, 30th percentile), and absolute Medicaid dollars remain negligible.
Competitive standing differs sharply by payer and code: the provider is a major national outlier on Medicare for K1034 (rank #119/30143; 100th percentile; extreme outlier), indicating exceptional scale for OTC COVID test provisioning on Medicare, whereas its Medicaid ranks are middle-to-lower (e.g., K1034 rank #3 of 5, U0003 rank #29 of 39), signaling only modest in-state presence for the same services. In short, this entity is nationally prominent for one Medicare code but not a clear statewide leader across Medicaid testing codes.
NPI tenure is relatively short: the NPI was enumerated 2021-08-16 (~5 years ago), implying the organization achieved its reported Medicare testing volumes within a recent multi-year window. Rapid scaling to the current reported volumes is consistent with pandemic-era test distribution activity.
Reimbursement profile shows notable differences across payers and codes: Medicare-paid average ($12 per claim for K1034) is higher than Medicaid-paid averages for the same code ($1 per claim), and Medicaid molecular code U0003 shows a $3 avg paid/claim while U0005 is reported at $0 avg. These per-claim payment differentials, combined with the heavy reliance on volume for revenue, indicate the provider’s financial model is sensitive to payer-specific reimbursement and claim mix.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 246,150 | $10 | $3M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 2 | 910 | 330 | $10 | $19.5K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 890 | $1 | $890 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 90 | $1 | $280 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 60 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Georgia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Georgia median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 29 | 40 | 850 | $70 | $983K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 29 | 40 | 740 | $20 | $122.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 3 | 10 | 890 | $1 | $1.8K |
Other providers in the same ZIP code as Advanced Medical Diagnostics Of Texas, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Pediatria Healthcare LLC | GA | Nursing Care Agency | $0 | $11.1M |
| La Clinica Del Nino PC | GA | Pediatrics Physician | $0 | $7.7M |
| Oxy-gen Laboratory LLC | GA | Clinical Medical Laboratory | $77.4K | $1.1M |
| Alpha Genomix Laboratories Inc | GA | Clinical Medical Laboratory | $0 | $1.1M |
| Rishi Singhal | GA | Retina Specialist (Ophthalmology) Physician | $668.8K | $0 |
| Sam Daliri | GA | General Practice Dentistry | $0 | $648.5K |
| Galina Vayner | GA | Internal Medicine Physician | $477.3K | $0 |
| Atlas Ambulance Inc | GA | Land Ambulance | $458.1K | $0 |
| Kendra Cole | GA | Specialist | $236.1K | $0 |
| Purnima Patel | GA | Ophthalmology Physician | $200.9K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.